Topic: First-in-Human Dose Selection

Scaling Volume of Distribution and Terminal Half-Life

Predicting Human Clearance with Simple Allometry

MABEL for Immune Agonists and High-Risk Biologics

MABEL for Target-Mediated Drug Disposition

MABEL from Biomarker Concentration-Response

Interpreting NOAEL and HNSTD for Starting-Dose Selection

Handling Species-Specific Pharmacology in MABEL

Incorporating Binding Kinetics into MABEL

Exposure Matching Across Animal and Human Doses

Estimating Allometric Exponents from Multispecies Data